INS and type 1 diabetes mellitus: Intrigued by their findings, this group further expanded their study and found that the continuous oral verapamil administration in patients with T1D might delay the loss of β-cell function and reduce the exogenous insulin requirements; while the discontinuation of verapamil treatment might lead to disease progression (Xu et al., 2022).